TrialJAMA oncology2020

Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.

Oliver Klein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.